Company Short-Term Debt: illumina.com (ILMN)

Public company logo of Illumina (ILMN)

Illumina's stable revenue is based on regular sales of consumables, as evidenced by the company's short-term debt, which is pegged at 0.09. However, export restrictions and DNA data laws are hindering global growth. The solution will be to modernize production lines for new genomic platforms, ensuring planned plant utilization and technological development.

ILMN (Illumina) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Illumina Platform (ILMN)

- stock price and consensus target price:
Stock Price Illumina|ILMN - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Illumina, Inc.|ILMN - Business Value
- shareholders' equity book value data:
Book Value per Share Illumina|ILMN - Book Capitalization|Market Value to Book Value Ratio illumina.com|ILMN - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Illumina, Inc.|ILMN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Illumina, Inc.|ILMN - Company Total Debt Obligations|Debts to Book Capitalization Illumina, Inc.|ILMN - Long-Term Debt Volume|Company Short-Term Debt Illumina|Quick Ratio illumina.com
- net income and valuation multiples indicators:
ILMN - Net Financial Result
Fundamental company analysis:Illumina (ILMN)
Flagship merchandise of Illumina, Inc.

Professional managers filter assets by assessing liquidity through the lens of short-term liabilities. This metric aggregates all loans maturing within one year, determining the risk of working capital deficits. For Illumina, Inc. (ILMN), this is critical when settling accounts with the network of external sequencer component suppliers. The stability of such payments ensures the uninterrupted assembly of systems. By analyzing short-term debt load on GURU.Markets, an investor can see the issuer's actual financial cushion.

Competitors of Illumina, Inc.

Agilent - Company Short-Term Debts|DGX - Company Short-Term Debts|Cologuard (EXAS) - Company Short-Term Debt|Company Short-Term Indebtedness RVTY|BIO (Bio-Rad Laboratories) - Company Short-Term Debts|Company Short-Term Debts anbio.com|Company Short-Term Debt Sotera Health (SHC)|Company Short-Term Debt QDEL (Quidel Corporation)|OPKO Corp - Company Current Liabilities|CareDx (CDNA) - Short-Term Debt|MRVI - Company Short-Term Debt|Short-Term Debt Volume fulgentgenetics.com FLGT|LAB: Company Short-Term Debts|CTKB - Short-Term Debt Volume|Company Short-Term Debt OraSure Technologies Inc|Exagen Diagnostics (XGN) - Short-Term Debt Volume|Company Short-Term Debts MDXH|Short-Term Debt Volume luciddx.com|Company Short-Term Debt Prenetics PRE|Insight Molecular Diagnostics, Inc. - Company Short-Term Debt|TRIB - Company Short-Term Debt|PRPH: Company Short-Term Debt|AIMD (Ainos, Inc.) - Company Current Liabilities|codiagnostics.com (CODX) - Company Short-Term Debts|Company Short-Term Debt HeartSciences|Company Current Liabilities Biomerica Inc. (BMRA)|Company Short-Term Debts CDIO|Short-Term Debt Volume Virax Biolabs Corp|Company Short-Term Debt Bluejay Diagnostics BJDX|AWH: Company Short-Term Indebtedness|Accelerate Diagnostics, Inc. - Company Short-Term Debts|CNTG - Company Short-Term Debts|ENZ (enzo.com) - Company Current Liabilities|Fresh2 Group - Company Short-Term Loans and Borrowings|GENE (Genetic Technologies Ltd) - Company Short-Term Debts|23andme.com (ME) - Short-Term Debt Volume|Company Short-Term Debt Psychemedics Corporation (PMD)